The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.
Related to this article
Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.
Advertisement
Advertisement
Trending on OncLive
1
Roswell Park Researchers Identify Strategy for Overcoming Resistance to RAS-Targeted Cancer Drugs
2
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma
3
How Biomarkers Now Drive First-Line Therapy in mHSPC
4
Coordinating the Timing of Interventions in NETs
5